A genome guided evaluation of the Lab4 probiotic consortium
A genome guided evaluation of the Lab4 probiotic consortium
复制标题
DOI：
10.1016/j.ygeno.2021.08.007
复制
发表时间：
2021-10-19
期刊：
影响因子：
4.4
通讯作者：
Facey, P. D.
中科院分区：
文献类型：
--
作者：
Baker, L. M.;Webberley, T. S.;Facey, P. D.
Lab 4益生菌聚生体的基因组序列草案保存在Genbank中：动物双歧杆菌乳酸亚种CUL 34（PRJNA 482550）、两歧双歧杆菌CUL 20（PRJNA 559984）、嗜酸乳杆菌CUL 60（PRJNA 482335）、嗜酸乳杆菌CUL 21（PRJNA 482434）。前生物基因组学分析证实了现有的分类，并确定了推定的基因序列，功能相关的性能，每种微生物在体外评估胆汁和酸的耐受性，粘附肠上皮细胞和抗生素的敏感性。基因组稳定性预测未发现抗生素抗性和毒力基因的基因获得的显著风险。这些观察结果得到了Wistar大鼠急性期和重复给药耐受性研究的支持。高剂量的Lab 4不会导致死亡、临床/组织病理学异常或全身毒性。在补充的大鼠中增加的Lab 4粪便数量意味着通过胃肠道存活和/或影响肠道微生物群组成。总之，这项研究为益生菌功能和Lab 4财团的安全性提供了多方面的支持。
Draft genome sequences of the Lab4 probiotic consortium were deposited in Genbank: Bifidobacterium animalis subsp lactis CUL34 (PRJNA482550), Bifidobacterium bifidum CUL20 (PRJNA559984), Lactobacillus acidophilus CUL60 (PRJNA482335), Lactobacillus acidophilus CUL21 (PRJNA482434). Probiogenomic analyses confirmed existing taxonomies and identified putative gene sequences that were functionally related to the performance of each organism during in vitro assessments of bile and acid tolerability, adherence to enterocytes and susceptibility to antibiotics. Genomic stability predictions identified no significant risk of gene acquisition of both antibiotic resistance and virulence genes. These observations were supported by acute phase and repeat dose tolerability studies in Wistar rats. High doses of Lab4 did not result in mortalities, clinical/histopathological abnormalities nor systemic toxicity. Increased faecal numbers of Lab4 in supplemented rats implied survival through the gastrointestinal tract and/or impact the intestinal microbiota composition. In summary, this study provides multifaceted support for probiotic functionality and the safety of the Lab4 consortium.